{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT03703856",
            "orgStudyIdInfo": {
                "id": "R01AG059640-01",
                "type": "NIH",
                "link": "https://reporter.nih.gov/quickSearch/R01AG059640-01"
            },
            "organization": {
                "fullName": "University of California, San Diego",
                "class": "OTHER"
            },
            "briefTitle": "Biomarker Predictors of Memantine Sensitivity in Patients With Alzheimer's Disease",
            "officialTitle": "Biomarker Predictors of Memantine Sensitivity in Patients With Alzheimer's Disease",
            "therapeuticArea": [
                "Neurology"
            ],
            "study": "biomarker-predictors-of-memantine-sensitivity-in-patients-with-alzheimer-s-disease"
        },
        "statusModule": {
            "statusVerifiedDate": "2023-12",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2019-01-31",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2024-06-30",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2024-06-30",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2018-10-09",
            "studyFirstSubmitQcDate": "2018-10-10",
            "studyFirstPostDateStruct": {
                "date": "2018-10-12",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2023-12-01",
            "lastUpdatePostDateStruct": {
                "date": "2023-12-08",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "PRINCIPAL_INVESTIGATOR",
                "investigatorFullName": "Neal R. Swerdlow, M.D., Ph.D.",
                "investigatorTitle": "Principal Investigator",
                "investigatorAffiliation": "University of California, San Diego"
            },
            "leadSponsor": {
                "name": "University of California, San Diego",
                "class": "OTHER"
            }
        },
        "oversightModule": {
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false,
            "isUsExport": true
        },
        "descriptionModule": {
            "briefSummary": "The effects of the medication, memantine, on brain functions and the symptoms of Alzheimer's Disease will be tested"
        },
        "conditionsModule": {
            "conditions": [
                "Alzheimer Disease"
            ],
            "keywords": [
                "Alzheimer's Disease",
                "Alzheimer Disease",
                "Alzheimer",
                "AD",
                "Alzheimer's"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE4"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "CROSSOVER",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "QUADRUPLE",
                    "whoMasked": [
                        "PARTICIPANT",
                        "CARE_PROVIDER",
                        "INVESTIGATOR",
                        "OUTCOMES_ASSESSOR"
                    ]
                }
            },
            "enrollmentInfo": {
                "count": 32,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Memantine",
                    "type": "ACTIVE_COMPARATOR",
                    "interventionNames": [
                        "Drug: Memantine"
                    ]
                },
                {
                    "label": "Placebo",
                    "type": "PLACEBO_COMPARATOR",
                    "interventionNames": [
                        "Drug: Placebo"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Memantine",
                    "description": "Phase 1 will test the acute effects of memantine (20 mg po) vs. placebo (PBO) on early auditory information processing measures in 32 carefully characterized patients with mild-to-moderate severity AD who are not currently taking AD medications. From this \"challenge\" test, a set of \"early auditory information processing memantine sensitivity\" measures will be derived for each patient. In Phase 2, all patients will begin an open-label trial of memantine monotherapy, titrated to 10 mg bid, with outcome measures collected after 8, 16 and 24 weeks of treatment. Medication adjustments are not restricted, and response heterogeneity is anticipated.",
                    "armGroupLabels": [
                        "Memantine"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Placebo",
                    "description": "Phase 1 will test the acute effects of memantine (20 mg po) vs. placebo (PBO) on early auditory information processing measures in 32 carefully characterized patients with mild-to-moderate severity AD who are not currently taking AD medications. From this \"challenge\" test, a set of \"Early auditory information processing P memantine sensitivity\" measures will be derived for each patient. In Phase 2, all patients will begin an open-label trial of memantine monotherapy, titrated to 10 mg bid, with outcome measures collected after 8, 16 and 24 weeks of treatment. Medication adjustments are not restricted, and response heterogeneity is anticipated.",
                    "armGroupLabels": [
                        "Placebo"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Change from baseline measure in Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-cog) at 8, 16 and 24 weeks",
                    "description": "measures cognitive ability",
                    "timeFrame": "0, 8, 16, 24 weeks"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Change from baseline measure in Neuropsychiatric Inventory-Questionnaire (NPI-Q) at 8, 16 and 24 weeks",
                    "description": "measures behavioral symptoms",
                    "timeFrame": "0, 8, 16, 24 weeks"
                }
            ],
            "otherOutcomes": [
                {
                    "measure": "Change from baseline measure in Geriatric Depression Scale (GDS) at 8, 16 and 24 weeks",
                    "description": "measures behavioral symptoms",
                    "timeFrame": "0, 8, 16, 24 weeks"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion:\n\n1. Alzheimer's Disease Research Center-confirmed diagnosis of AD\n2. Mini-Mental State Examination (MMSE) score 10-22 OR a Montreal Cognitive Assessment (MOCA) score of 15-24\n3. Age 50-83 y\n4. Knowledgeable caregiver\n5. Ambulatory\n6. Medically stable;\n7. Audiometric testing (detection \\< 40 db(A) at 1000 Hz)\n8. Informed consent\n\nExclusion:\n\n1. Active systemic illness (e.g. heart disease, liver failure, renal insufficiency, cancer, HIV, tuberculosis, Hepatitis C)\n2. Current psychiatric or neurologic illness other than AD\n3. History of vascular disease, myocardial infarction, cerebrovascular accidents, transient ischemic attack, seizure, head injury with loss of consciousness; substance dependence (including alcohol and Opioid)\n4. Past treatment with memantine; unable to tolerate acetylcholinesterase inhibitor\n5. Investigational drug treatment \\< 30 d of screening\n6. Current meds: amantadine, riluzole, other pro-cognitive medication, opioids\n7. Positive urine toxicology for non-prescribed psychoactive substance\n8. Actively enrolled in cognitive remediation therapy",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "50 Years",
            "maximumAge": "83 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Joyce Sprock",
                    "role": "CONTACT",
                    "phone": "(619) 471-9455",
                    "email": "jsprock@ucsd.edu"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Neal Swerdlow, M.D., Ph.D.",
                    "affiliation": "UCSD",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "Clinical Teaching Facility (CTF-B102) at UCSD Medical Center",
                    "status": "RECRUITING",
                    "city": "San Diego",
                    "state": "California",
                    "zip": "92103",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Jo Talledo, B.A.",
                            "role": "CONTACT",
                            "phone": "619-543-3093",
                            "email": "atalledo@ucsd.edu"
                        },
                        {
                            "name": "Neal R. Swerdlow, M.D., Ph.D.",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 32.71533,
                        "lon": -117.15726
                    }
                }
            ]
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000000544",
                    "term": "Alzheimer Disease"
                }
            ],
            "ancestors": [
                {
                    "id": "D000003704",
                    "term": "Dementia"
                },
                {
                    "id": "D000001927",
                    "term": "Brain Diseases"
                },
                {
                    "id": "D000002493",
                    "term": "Central Nervous System Diseases"
                },
                {
                    "id": "D000009422",
                    "term": "Nervous System Diseases"
                },
                {
                    "id": "D000024801",
                    "term": "Tauopathies"
                },
                {
                    "id": "D000019636",
                    "term": "Neurodegenerative Diseases"
                },
                {
                    "id": "D000019965",
                    "term": "Neurocognitive Disorders"
                },
                {
                    "id": "D000001523",
                    "term": "Mental Disorders"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M3885",
                    "name": "Alzheimer Disease",
                    "asFound": "Alzheimer's Disease",
                    "relevance": "HIGH"
                },
                {
                    "id": "M10018",
                    "name": "Hypersensitivity",
                    "relevance": "LOW"
                },
                {
                    "id": "M6904",
                    "name": "Dementia",
                    "relevance": "LOW"
                },
                {
                    "id": "M5204",
                    "name": "Brain Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M5742",
                    "name": "Central Nervous System Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M23002",
                    "name": "Tauopathies",
                    "relevance": "LOW"
                },
                {
                    "id": "M21558",
                    "name": "Neurodegenerative Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M21836",
                    "name": "Neurocognitive Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M4815",
                    "name": "Mental Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M14473",
                    "name": "Psychotic Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "T2192",
                    "name": "Familial Alzheimer Disease",
                    "asFound": "Alzheimer's Disease",
                    "relevance": "HIGH"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC10",
                    "name": "Nervous System Diseases"
                },
                {
                    "abbrev": "BXM",
                    "name": "Behaviors and Mental Disorders"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC20",
                    "name": "Immune System Diseases"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000008559",
                    "term": "Memantine"
                }
            ],
            "ancestors": [
                {
                    "id": "D000000978",
                    "term": "Antiparkinson Agents"
                },
                {
                    "id": "D000018726",
                    "term": "Anti-Dyskinesia Agents"
                },
                {
                    "id": "D000015259",
                    "term": "Dopamine Agents"
                },
                {
                    "id": "D000018377",
                    "term": "Neurotransmitter Agents"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                },
                {
                    "id": "D000045505",
                    "term": "Physiological Effects of Drugs"
                },
                {
                    "id": "D000018691",
                    "term": "Excitatory Amino Acid Antagonists"
                },
                {
                    "id": "D000018683",
                    "term": "Excitatory Amino Acid Agents"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M11542",
                    "name": "Memantine",
                    "asFound": "A 12-",
                    "relevance": "HIGH"
                },
                {
                    "id": "M4295",
                    "name": "Antiparkinson Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M7473",
                    "name": "Dopamine",
                    "relevance": "LOW"
                },
                {
                    "id": "M17962",
                    "name": "Dopamine Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M20504",
                    "name": "Neurotransmitter Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M20771",
                    "name": "Excitatory Amino Acid Antagonists",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "AnDyAg",
                    "name": "Anti-Dyskinesia Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                },
                {
                    "abbrev": "CaAg",
                    "name": "Cardiotonic Agents"
                }
            ]
        }
    },
    "hasResults": false
}